Introduction
============

Among the various biomedical imaging modalities, magnetic resonance imaging (MRI) -- which provides high-resolution anatomical images in a noninvasive manner -- is one of the most powerful tools.[@b1-ijn-13-4607],[@b2-ijn-13-4607] In 40%--50% cases of clinical application, magnetic resonance (MR) contrast agents (CAs) are introduced to enhance the contrast, presenting improved sensitivity and quality of the images for more accurate diagnosis.[@b3-ijn-13-4607] MRI CAs, generally in the form of T~1~-positive and T~2~-negative CAs, greatly improve the sensitivity of MRI by affecting the rate of water proton relaxation. For T~1~-weighted CAs, paramagnetic complexes containing gadolinium (Gd^3+^) and manganese (Mn^2+^) ions are commonly used to effectively accelerate the T~1~ relaxation process to produce a brighter image.[@b4-ijn-13-4607]--[@b9-ijn-13-4607] In contrast, T~2~-weighted CAs, such as the superparamagnetic iron oxide nanoparticles (SPIOs), exhibit strong magnetization when an external magnetic field is applied. This causes microscopic field inhomogeneity and activates the dephasing of protons to produce decreased signal intensity in T~2~- and T~2~\*-weighted MR images.[@b10-ijn-13-4607],[@b11-ijn-13-4607] However, each modal CA has its own unique advantages and limitations. For example, the commonly used T~1~ CAs are relatively small molecules, which are fast excreted by the kidneys, thereby resulting in difficulty with high-resolution image acquisition. Moreover, the functionalization of paramagnetic complexes with targeting molecules is hampered by the arduous and complex modification process.[@b12-ijn-13-4607]--[@b14-ijn-13-4607] On the other hand, SPIOs as T~2~ MR CAs are very useful for biomedical applications because they are not subject to strong magnetic interactions in dispersion and are readily stabilized under physiological conditions.[@b15-ijn-13-4607] However, the biggest issue with using T~2~ CAs is that it is difficult to distinguish the signal from an air bubble or image artifact. Due to the negative contrast effect and susceptibility artifacts, it is difficult to distinguish the region of signals induced by SPIOs from low-level background MR signals, such as signals arising from adjacent tissues, bone, or vasculature.[@b11-ijn-13-4607] Furthermore, independent T~1~ or T~2~ MR imaging suffers from false-positive signals that are ubiquitously observed in tissues. Last but not the least, T~1~--T~2~ dual imaging displays obvious advantages over single imaging with regard to water and fat molecules in tissue. For example, some tissue components such as the bone and fiber components present low signals on T~1~WI similar to water. Moreover, some tissue components such as bleeding and mucus present high signals on the T~1~WI similar to fat. It is difficult to distinguish water and fat with single imaging. However, with T~1~--T~2~ dual imaging, these issues can be addressed. Water presents a low signal on T~1~WI and a high signal on T~2~WI. Fat presents a high signal on both T~1~WI and T~2~WI. Thus, it is easy to recognize water and fat with dual imaging. Therefore, the development of T~1~--T~2~ dual CAs is emerging attractively because they have the ability to validate reconstruction and visualization of the data in a more accurate and reliable manner, and to acquire complementary and self-confirmed information to permit meaningful interpretation.[@b16-ijn-13-4607] Several kinds of dual CAs have been reported to improve the diagnostic accuracy of diseases.[@b17-ijn-13-4607]--[@b24-ijn-13-4607] Choi et al developed a nanoparticle (NP)-based dual CA -- MnFe~2~O~4~\@SiO~2~\@Gd~2~O(CO~3~)~2~ -- which not only possessed superior MR contrast effects, but also had the unique capability of displaying "AND" logic signals in both T~1~ and T~2~ modes.[@b22-ijn-13-4607] Bae et al synthesized Gd-labeled Fe~3~O~4~ NPs and demonstrated their capability as dual CAs for T~1~- and T~2~-weighted MRI.[@b21-ijn-13-4607]

For the design of T~1~--T~2~ dual CAs, two main aspects should be concerned. Firstly, to obtain high sensitivity, the T~1~ and T~2~ CAs themselves should possess good MRI relaxivities. High relaxivity is the primary requisite for the development of molecular imaging MR probes and targeting probes.[@b25-ijn-13-4607]--[@b27-ijn-13-4607] Several strategies for increasing the sensitivity (relaxivity) of MRI CAs have been well reviewed.[@b28-ijn-13-4607]--[@b30-ijn-13-4607] Secondly, the undesirable T~1~ signal quenching of the paramagnetic T~1~ CA by the magnetic field generated by a superparamagnetic T~2~ CA when they are in proximity should be avoided. To address these issues, in this study, we aimed to synthesize the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex ([Scheme 1](#f14-ijn-13-4607){ref-type="fig"}) and explore its potential as a T~1~--T~2~ dual CA to obtain better MRI contrast enhancement and specific tumor cell targeting. BSA-Gd~2~O~3~ NPs and Fe~3~O~4~ NPs were chosen as T~1~ and T~2~ MRI CAs. High-Gd density paramagnetic ultrasmall gadolinium oxide nanoparticles (Gd~2~O~3~ NPs) have emerged to present larger T~1~ relaxivity, good biocompatibility, and easy conjugation with other biomolecules or imaging agents for molecular MRI (mMRI) and multimodal molecular imaging.[@b18-ijn-13-4607],[@b31-ijn-13-4607],[@b32-ijn-13-4607] The mesoporous silica nanoshell was introduced to coat Fe~3~O~4~ NPs and load BSA-Gd~2~O~3~ NPs as well as to act as a spacer to minimize the magnetic spin interactions between T~1~ and T~2~ CAs. It has been proved that the magnetic field generated by a superparamagnetic T~2~ CA could perturb the electronic spins of paramagnetic T~1~ CA when they are in close proximity (\<12 nm).[@b22-ijn-13-4607] Furthermore, to realize the specific tumor cell imaging, an AS1411 aptamer, which can selectively bind with nucleolin overexpressed on a variety of cancer cells, was employed as the tar geting molecule for the fabrication of the mMRI nanoprobe -- Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411.[@b33-ijn-13-4607]--[@b35-ijn-13-4607] Its ability for the specific targeting of renal cell carcinoma (RCC) was confirmed by the T~1~--T~2~-weighted MRI.

Materials and methods
=====================

Materials and reagents
----------------------

Bovine serum albumin (BSA) was obtained from Solarbio (Beijing, People's Republic of China). Gd(NO~3~)~3~·6H~2~O, hexadecyl trimethyl ammonium bromide (CTAB), and dimethyl sulfoxide (DMSO) were purchased from Sinopharm Chemical Reagent Co. Ltd., Beijing, People's Republic of China Tetraeth-ylorthosilicate (TEOS), poly(dimethyl diallyl ammonium chloride) (PDDA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC·HCl), and N-hydroxysuccinimide (NHS) were purchased from Sigma-Aldrich (Saint Louis, MO, USA). DNA oligos were synthesized and purified by Shanghai Sangon Biotechnology Co. Ltd. (Shanghai, People's Republic of China); 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was obtained from Sunshine Biotech. Co. Ltd. (Nanjing, People's Republic of China). Cell culture media including HDMEM, RPMI 1640, and fetal calf serum were obtained from Kangmei Biotechnology Co. Ltd (Xuzhou, People's Republic of China). All other reagents were of analytical grade and used without purification. All aqueous solutions were prepared using ultrapure water from a Milli-Q system (Millipore, Boston, MA, USA). The DNA sequence is listed as follows.

COOH-AS1411:

5′-COOH-GGTGGTGGTGGTTGTGGTGGTGGTGG-3′.

Apparatus and characterization
------------------------------

The size and morphology of NPs were observed by transmission electron microscopy (TEM; TECNAI G2, FEI Company, Hillsboro, OR, USA). Fourier transform infrared absorption (FTIR) spectra were obtained through FTIR spectroscopy (Bruker, Billerica, MA, USA). Zeta potentials were determined by Nano ZS90 (Malvern Panalytical Ltd, Malvern, England). X-ray powder diffraction (XRD) patterns were obtained by using a X-ray powder diffractometer (D8 ADVANCE, Bruker). The determinations of Gd and iron ion concentrations were undertaken with inductively coupled plasma-mass spectrometry (ICP-MS) (Optima 5300DV, PerkinElmer, San Diego, CA, USA). The absorbances for MTT assay were determined by a microplate reader (Multiskan MK3, Thermo Fisher Scientific, Waltham, MA, USA) at 490 nm. MRI scanning was conducted on a Signa HDxt 3.0T, General Electric Company, Boston, Massachusetts, USA. Hematologic and biochemical analysis was carried out with a hematology analyzer (Mindray BC-5390, Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, People's Republic of China) and cobas connection modules (Roche Diagnostics, Basel, Switzerland), respectively.

Cells and cell culture conditions
---------------------------------

The 786-0 renal carcinoma cells and NIH-3T3 mouse fibroblast cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, People's Republic of China). The 786-0 renal carcinoma cells were cultured in a 10% FBS-containing RPMI 1640 medium (Sijiqing, People's Republic of China) supplemented with penicillin (100 mg/mL) and streptomycin (100 mg/mL). NIH-3T3 cells were propagated in 10% FBS-containing Dulbecco's Modified Eagle's Medium (Gibco, Grand Island, NY, USA) supplemented with penicillin (100 mg/mL) and streptomycin (100 mg/mL). All cells were grown in a humidified incubator (Thermo Fisher Scientific) at 37°C under 5% CO~2~ atmosphere.

Preparation of Fe~3~O~4~ NPs
----------------------------

The Fe~3~O~4~ NPs were synthesized using a previously reported method.[@b36-ijn-13-4607] In brief, approximately 10 mL water containing 1.0 mol/L Fe^3+^ and 0.5 mol/L Fe^2+^ ions (molar ratio 2:1) was stirred at 400 rpm on a stir plate for 20 min. Then, 30 mL ammonium hydroxide was slowly added to the solution and the speed was increased to 900 rpm in order to uniformly precipitate magnetic NPs. Fe~3~O~4~ NPs were obtained 30 min later. They were washed with distilled water until the pH value decreased to 7.0. Finally, the obtained Fe~3~O~4~ NPs were dispersed in distilled water at a concentration of 0.24 mg/mL until further use.

Synthesis of Fe~3~O~4~\@mSiO~2~ core-shell NPs
----------------------------------------------

In a typical procedure,[@b37-ijn-13-4607] CTAB (50 mg) was dissolved in 20.8 mL distilled water. In total, 4.2 mL Fe~3~O~4~ and NaOH solution (2.00 M, 160 µL) were added to the above CTAB solution sequentially. Then, the mixture was heated to 70°C with stirring, and 250 µL TEOS and 500 µL ethylacetate were added to the reaction solution in sequence. The mixture was stirred for 3 h at 70°C. The resultant precipitate was washed 3 times with ethanol to remove the unreacted species and then dispersed in 20 mL ethanol. To extract CTAB, 20 µL HCl was added to the dispersion mixture (pH\>1.0) and stirred for 3 h at 60°C. To obtain hollow mesoporous silica, more HCl was used for extraction (pH \<1.0). After washing three times with ethanol, the Fe~3~O~4~\@mSiO~2~ NPs were dried at 50°C.

Preparation of BSA-Gd~2~O~3~ NPs
--------------------------------

BSA-Gd~2~O~3~ NPs were synthesized according to the methods specified in the literature with some modifications.[@b38-ijn-13-4607] In total, 0.25 g BSA was dissolved in 9 mL distilled water. Then, 1 mL 50 mM Gd(NO~3~)~3~ was added to the above solution slowly under vigorous stirring. After the introduction of 1 mL 2 M NaOH 5 min later, the mixture was allowed to react under vigorous stirring at 37°C for 12 h. Finally, the BSA-Gd~2~O~3~ thus prepared was dialyzed against distilled water (1:1,000, v/v) to remove excess precursors.

Fabrication of Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 mMRI nanoprobe
--------------------------------------------------------------------------

The Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ was prepared through electrostatic interaction.[@b39-ijn-13-4607] Initially, Fe~3~O~4~\@mSiO~2~ (3 mg) and PDDA solution (2 mL, 2 mg/mL, 0.2 M NaCl) were mixed under sonication for 40 min, and the excess polyelectrolyte was removed by washing with water. Then, the positively charged magnetic particles were dispersed in distilled water (500 µL), and BSA-Gd~2~O~3~ (50 µL, 1.06 µM Gd) was added and sonicated for 40 min. After washing with water, the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ were dispersed in 2 mL water for MRI scanning. Meanwhile, to obtain the best MRI behavior, different concentrations of BSA-Gd~2~O~3~ NPs (0.212, 0.636, 1.06, 1.484, and 1.908 µM Gd) and Fe~3~O~4~ (1, 3, and 5 mg) were tested. At the optimized condition, the AS1411 aptamer was functionalized onto the surface of Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ NPs by covalent coupling between the amino group of BSA-Gd~2~O~3~ and the carboxyl group modified at the 5′ end of AS1411 aptamer with the help of EDC and NHS.[@b40-ijn-13-4607] Briefly, 100 µM COOH-AS1411 (50 µL) was mixed with EDC (100 µL, 10 mg mL^−1^) in 300 µL PBS (10 mM, pH 7.4) and incubated at 37°C for 15 min to form an active carboxyl group. Then, NHS (100 µL, 10 mg mL^−1^) and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ (500 µL, 5.0 mg mL [@b1-ijn-13-4607]) were added to the mixture and reacted at 37°C for 2 h. The unreacted biomolecules were removed by two centrifugation/washing cycles. Finally, the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobes were dispersed in 1 mL PBS (10 mM) at pH 7.4 for further use.

Relaxivity calculation of Fe~3~O~4~ NPs, BSA-Gd~2~O~3~ NPs, Gd-DTPA, and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex
--------------------------------------------------------------------------------------------------------------------------

The MRI behavior test of BSA-Gd~2~O~3~ and Fe~3~O~4~ was conducted with a 3.0 T human MR scanner (General Electric Company). Various concentrations of BSA-Gd~2~O~3~ and Fe~3~O~4~ solution were prepared before MRI scanning, which varied from 0.212 to 1.908 µM with a volume of 600 µL for BSA-Gd~2~O~3~ NPs, and 1--5 mg for Fe~3~O~4~ NPs. The following parameters were adopted in data acquisition. 1) T~1~-weighted images: echo time (TE)=16.5 ms, repetition time (TR)=420 ms, field of view (FOV)=14×14 cm, matrix=384×256, slice thickness=2.0 mm, spacing=0.2 mm; and 2) T~2~-weighted images: echo time (TE)=90.7 ms, repetition time (TR)=4,500 ms, field of view (FOV)=14×14 cm, matrix=384×256, slice thickness=2.0 mm, spacing=0.2 mm. Quantitative T~1~ and T~2~ relaxation maps were reconstructed from datasets using function software at a workstation (ADW 4.2). The signal intensities of the samples were measured, and the T~1~ and T~2~ values were calculated accordingly. MRI scanning of Gd-DTPA and the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex with different concentrations was carried out in the same way.

The T~1~ relaxivity values of the BSA-Gd~2~O~3~, Gd-DTPA, and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex were determined by measuring longitudinal proton relaxation time (T~1~) as a function of Gd concentration. The T~2~ relaxivity values of the Fe~3~O~4~ and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex were determined by measuring the lateral proton relaxation time (T~2~) as a function of Fe concentration.

MTT assay
---------

The 786-0 cells and NIH-3T3 cells were cultured on 96-well plates at a density of 10^4^ cells each well. After 24-h incubation, the medium was substituted with 100 µL fresh medium containing different concentrations of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (0, 200, 400, 600, 800, 1,000, 1,200, and 1,400 µg mL^−1^). After 24-h incubation, the medium was removed, and fresh medium (100 µL) containing MTT (20 µL, 5 mg mL^−1^) was added into each well. Four hours later, the culture medium was carefully removed and washed, and 100 mL DMSO was added to each well to dissolve the formazan crystals for 10 min. The absorbance at 490 nm was measured by a microplate reader (Multiskon MK3, USA).

Stability test
--------------

The Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex was dispersed in RPMI 1640 culture medium. At different time points (0, 2, 4, 6, 8, 12, 24, 48, and 72 h), 100 µL samples were collected and centrifuged at 25,000 rpm for 30 min to obtain the supernatant. The concentrations of Fe and Gd ions in the supernatant were determined by ICP-MS. For the pH stability test, the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex was dispersed in solutions of different pHs (pH 4, 5, 6, 7, 8, 9, and 10) and incubated for 24 h. The concentrations determined for Fe and Gd ions were the same as mentioned earlier.

Specific MR imaging of 786-0 cells with Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 mMRI nanoprobe in vitro
------------------------------------------------------------------------------------------------------------

The 786-0 cells and NIH-3T3 cells were seeded into six-well plates at a density of 10^5^ cells/well and cultured for 24 h in a humidified incubator at 37°C under 5% CO~2~ atmosphere, respectively. Then, the culture media was removed and the cells were washed with PBS twice. In total, 500 µL of different concentrations of Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobe (0.5, 1, and 2.5 mg mL^−1^) and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (0.5, 1, and 2.5 mg mL^−1^) were added into the well and incubated for 1 h at 37°C. After discarding the nanoprobe, the cells were washed and lysed by trypsin. The harvested cells were fixed with 600 µL 1% agarose for MRI scanning. The untreated cells that were incubated with PBS were taken as the control.

Biodistribution of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex in the mouse
-------------------------------------------------------------------------------------

The residual nanocomplex in heart, liver, kidneys, and lungs after 1 h and 24 h post-injection of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex was determined by the quantification of the Gd element by ICP-MS. Briefly, six Kunming mice were divided into two groups: 1-h post-injection and 24-h post-injection. Each mouse was injected with the same concentration of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (0.16 mmol Gd per kg body weight). The mice were sacrificed and the major organs, including heart, liver, kidneys, and lungs, were collected at 1 h and 24 h post-injection. To these organs, 2 mL aqua regia (HCl:HNO~3~=3:1) was added and the organs in aqua regia were heated to 200°C for 1 h. After being cooled to room temperature, 2 mL H~2~O was added and a 0.22-µm filter was introduced to remove undigested tissues.[@b41-ijn-13-4607] The Gd concentrations were then analyzed by ICP-MS.

In vivo toxicity evaluation of Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex
--------------------------------------------------------------------------------

Hematologic and biochemical analyses were introduced to evaluate the in vivo toxicity of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex. In total, six Kunming mice were divided into two groups: the normal saline group and the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex group. The mice were injected with normal saline and the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (0.16 mmol Gd per kg body weight) via tail vein, respectively. After 1 week, blood was harvested by cardiac puncture. Hematologic analysis including platelets (PLT), hematocrit (HCT), hemoglobin (HGB), red blood cells (RBC), white blood cells (WBC), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) was undertaken on a hematology analyzer. The biochemical effects of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex for alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), creatinine (CREA), total protein (TP), albumin (ALB), and total biliru-bin (TBIL) were evaluated by cobas connection modules.

In vivo MRI
-----------

Animal experiments were conducted in accordance with the National Institutes of Health guidelines on the use of animals in research, and were approved by the Animal Care Committee of Xuzhou Medical University. Healthy BALB/c mice weighing 20--30 g were chosen for in vivo MRI study. The mice were anesthetized by intraperitoneal injection of 2% mebumalnatrium (4 µL/g bodyweight), followed by tail-vein administration of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (0.16 mmol Gd per kg body weight). Then, at scheduled intervals, T~1~WI images and T~2~WI images were acquired by a 3.0 T MR imaging system (GE Discovery 750W, USA) with the animal T/R coil (Magtron Inc., Jiangyin, People's Republic of China). The sequences for T~1~-weighted images were set as follows: TE=12 ms; TR=400 ms; FOV=80×80 mm; slice thickness=2 mm; spacing=0.2 mm; and matrix=256×256. The sequences for T~2~-weighted images were set as follows: TE=58 ms; TR=300 ms; FOV=80×48 mm; slice thickness=2 mm; spacing=0.2 mm; and matrix=256×256. To compare the signal intensity at different time points, the same protocols, prone position, and the same scanning landmark of MRI were required. The relative intensity changes of the same region of interest on the same slice in the same window width and window level were recorded by software in the workstation GE AW4.6.

Results
=======

Characterization of Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 mMRI nanoprobe
-------------------------------------------------------------------------------

For the fabrication of the T~1~--T~2~ dual CA, 10.7-nm-sized-Fe~3~O~4~ NPs as T~2~ CA were first encased with an mSiO~2~ nanoshell ([Figure S1](#SD1-ijn-13-4607){ref-type="supplementary-material"}). An approximately 20-nm nanoshell could reduce the quenching effect of Fe~3~O~4~ NPs on the T~1~ signal to the extent that was possible. Then, BSA-Gd~2~O~3~ NPs were deposited onto the Fe~3~O~4~\@mSiO~2~ surface through layer-by-layer assembly with the help of polyelectrolytes and PDDA. Driven by the electrostatic force, a uniform monolayer of positively charged PDDA and negatively charged BSA-Gd~2~O~3~ NPs were alternatively adsorbed onto the negatively charged Fe~3~O~4~\@mSiO~2~ NPs. This assembly process was monitored by the determination of the changes of zeta potentials. As shown in [Figure 1A](#f1-ijn-13-4607){ref-type="fig"}, the potential value of Fe~3~O~4~\@mSiO~2~ NPs was −33.5 mV and changed to 47.8 mV with PDDA assembly. The zeta potential of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex was 26.9 mV, which might derive from the negatively charged BSA. The corresponding hydrodynamic diameters of Fe~3~O~4~\@mSiO~2~, Fe~3~O~4~\@mSiO~2~/PDDA and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ were changed from 100.2 to 297.4 and 345.6 nm, accordingly ([Figure 1B](#f1-ijn-13-4607){ref-type="fig"}). From XRD patterns in [Figure S2](#SD2-ijn-13-4607){ref-type="supplementary-material"}, the typical diffraction peaks of Fe~3~O~4~ were observed. The amorphous hump of SiO~2~ at around 26° and the characteristic peaks of Fe~3~O~4~ could be observed in Fe~3~O~4~\@mSiO~2~ and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~, indicating the successful fabrication of the nanocomplex.[@b42-ijn-13-4607] Then, the further conjugation of the AS1411 aptamer with the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex through a covalent coupling reaction was confirmed by the FTIR absorption spectrum and UV-vis absorption spectrum. The emerging absorption peak at 1,630 and 1,652 cm^−1^ was ascribed to acyl-amide vibration in the FTIR absorption spectrum ([Figure 1C](#f1-ijn-13-4607){ref-type="fig"}), and a characteristic UV-vis absorbance peak of the AS1411 aptamer could be observed in the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobe ([Figure 1D](#f1-ijn-13-4607){ref-type="fig"}), both indicating the successful preparation of the mMRI nanoprobe.

MRI behavior of Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex
-----------------------------------------------------------------

To explore its potential as an mMRI nanoprobe, the MRI behavior of our synthesized Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex was first evaluated. With different concentrations of BSA-Gd~2~O~3~ NPs, the T~1~ and T~2~ relaxation times of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex varied. As shown in [Figures 2](#f2-ijn-13-4607){ref-type="fig"} and [3](#f3-ijn-13-4607){ref-type="fig"}, with the increase of the BSA-Gd~2~O~3~ NP concentration, the T~1~ relaxation time of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex was enhanced and reached a maximum of approximately 320 ms in the presence of 1.06 µM Gd. However, the further increased concentration of BSA-Gd~2~O~3~ NPs (1.484 and 1.908 µM Gd) influenced the T~1~ relaxation time of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex non-obviously. Unlike the T~1~ relaxation time, the T~2~ relaxation time of Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex changed irregularly with the increase in the concentration of BSA-Gd~2~O~3~ NP. However, when the BSA-Gd~2~O~3~ NP concentration was 1.06 µM Gd, the T~2~-map color image was darkest. The influence of Fe~3~O~4~ concentrations on the T~1~ and T~2~ relaxation times were not as strong as that of BSA-Gd~2~O~3~ NPs. As shown in [Figure S3](#SD3-ijn-13-4607){ref-type="supplementary-material"} and [Table S1](#SD8-ijn-13-4607){ref-type="supplementary-material"}, with the increase of the Fe~3~O~4~ concentration, the T~1~ relaxation time of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex was weakened; however, its T~2~ relaxation time changed little. For overall consideration, 50 µL 1.06 µM BSA-Gd~2~O~3~ and 1 mg Fe~3~O~4~ NPs were chosen for the fabrication of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex in the following experiments.

To testify the influence of BSA-Gd~2~O~3~ NPs of our nano-complex on T~2~WI, we also synthesized the Fe~3~O~4~\@mSiO~2~ nanocomplex and the mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocom-plex. As shown in [Figure S4](#SD4-ijn-13-4607){ref-type="supplementary-material"} and [Table S2](#SD9-ijn-13-4607){ref-type="supplementary-material"}, the T~2~ signals of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex and the Fe~3~O~4~\@mSiO~2~ nanocomplex were all less than the T~2~ signal of the mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex; however, there was little change between the T~2~ signal of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex and the T~2~ signal of the Fe~3~O~4~\@mSiO~2~ nanocomplex. Thus, in our prepared nanocomplex, the BSA-Gd~2~O~3~ NPs had no obvious effect on T~2~WI, and Fe~3~O~4~ NPs influenced the T~2~ signal obviously. From the above results, we can conclude that, for the synthesis of T~1~--T~2~ dual MRI CA Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~, T~1~ and T~2~ signals are ascribed to the BSA-Gd~2~O~3~ NPs and Fe~3~O~4~ core, respectively.

Then, the T~1~ relaxivity values of Gd-DTPA, BSA-Gd~2~O~3~ NPs, and the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex were determined and compared by measuring longitudinal proton relaxation time (T~1~) as a function of Gd concentration. As shown in [Figure 4](#f4-ijn-13-4607){ref-type="fig"}, the *r*~1~ value of BSA-Gd~2~O~3~ was 12.2 s^−1^ mM^−1^, which was three times that of the commercial MRI CAs, Gd--DTPA (*r*~1~=4.3 s^−1^ mM^−1^). The T~1~ relaxivity of Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex was 11.5 s^−1^ mM^−1^. For the determination of the T~2~ relaxivity values of Fe~3~O~4~ and the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex, lateral proton relaxation times (T~2~) as a function of Fe concentration were measured. The T~2~ relaxivity of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ (195.1 s^−1^ mM^−^ Fe) was lower than that of Fe~3~O~4~ (345.9 s^−1^ mM^−1^ Fe), but higher than the clinically used Feridex (108 s^−1^ mM^−1^ Fe)[@b1-ijn-13-4607] and the relaxivity reported for Fe~3~O~4~ \@mSiO~2~NPs (171.6 s^−1^ mM^−1^ Fe; [Figure 5](#f5-ijn-13-4607){ref-type="fig"}).[@b43-ijn-13-4607],[@b44-ijn-13-4607] Such excellent MR imaging behavior indicated the ability of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nano-complex (the molar value of Fe/Gd equals 0.539; *r*~1~/*r*~2~ equals 0.0567) as a promising T~1~--T~2~ dual MRI CA for the fabrication of an mMRI nanoprobe to specifically image tumor cells.

In vitro cytotoxicity test
--------------------------

Before the use of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex for specific tumor cell imaging, it is vital to assess its safety in vitro. The MTT assay was conducted to evaluate the cell toxicity of the nanocomplex and identify potentially safe concentrations for the following targeting experiments. The Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nano-complex with eight different concentrations, ranging from 0 to 1,400 µg/mL, was incubated with 786-0 and NIH-3T3 cells for 24 h, respectively. As shown in [Figure 6](#f6-ijn-13-4607){ref-type="fig"}, the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex displayed good bio-compatibility, and no significant cytotoxicity was observed both on 786-0 renal carcinoma or NIH-3T3 cells.

Stability test
--------------

The leaching of metallic ions is a potential harmful effect of their biological application. To test the possibility of Gd and Fe ions leaching from the nanocomplex in biological media, we determined the concentrations of Gd and Fe ions in the supernatant with the passage of time from when the nanocomplex was dispersed in the cell culture medium and in different pH solutions incubated for 24 h. As shown in [Figure 7](#f7-ijn-13-4607){ref-type="fig"}, no obvious Gd and Fe ion leaching could be observed with time in the cell culture medium or different pH solutions, indicating the good stability of our fabricated nanocomplex.

In vitro specific T~1~--T~2~ dual MR imaging of tumor cells
-----------------------------------------------------------

Finally, the specific cellular targeting of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 mMRI nanoprobe was evaluated by T~1~--T~2~ MRI. AS1411 is a nucleolus of specific nucleic acid aptamers, which can specifically combine with nucleolin on the surface of the tumor cell. As shown in [Figure S5](#SD5-ijn-13-4607){ref-type="supplementary-material"}, the AS1411 modification did not produce a significant influence on the MRI behavior of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex, indicating the potential use of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 as an mMRI nanoprobe.

To validate the specific targeting ability of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 mMRI nanoprobe, the 786-0 cells were incubated with the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 mMRI nanoprobes, respectively. For the achievement of the best signal-to-noise value, 0.5, 1, and 2.5 mg mL^−1^ nanoprobes were introduced and compared. As shown in [Figures 8](#f8-ijn-13-4607){ref-type="fig"} and [9](#f9-ijn-13-4607){ref-type="fig"}, the higher the concentration of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobe, the brighter the T~1~ signal intensity and the darker the T~2~ signal intensity from 786-0 cells. Furthermore, the presence of the AS1411 aptamer could facilitate more of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobe to bind with 786-0 cells and present a brighter T~1~ signal and a darker T~2~ signal at all three concentrations. However, when the concentration of the nanoprobe reached 2.5 mg mL^−1^, the nonspecific adsorption obviously increased. Thus, 1 mg mL^−1^ of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobe was chosen for the specific MRI finally. To further confirm such AS1411 aptamer-based specific targeting, NIH-3T3 cells were introduced as the control and treated with 1 mg of the mL^−1^ Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nano-probe, Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex, respectively. No significant difference existed between these two groups in both T~1~ and T~2~ signal, indicating the specific MRI ability of our synthesized nanoprobe to ccRCC in vitro ([Figure S6](#SD6-ijn-13-4607){ref-type="supplementary-material"}, [Tables S3](#SD10-ijn-13-4607){ref-type="supplementary-material"} and [S4](#SD11-ijn-13-4607){ref-type="supplementary-material"}).

Biodistribution of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex in the mouse
-------------------------------------------------------------------------------------

To show the biodistribution and residual persistence of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex in different organs, ICP-MS was employed to determine the Gd concentration in the heart, liver, kidneys, and lungs after 1 h and 24 h following injection of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex. As shown in [Figure 10](#f10-ijn-13-4607){ref-type="fig"}, the Gd concentration in the above organs all decreased, except in the kidney. The residual Gd concentrations in heart, liver, kidneys, and lungs were 1.90±0.12, 2.41±0.06, 2.15±0.08, and 2.27±0.1 µg/g at 1 h post-injection and 1.54±0.11, 1.94±0.12, 2.46±0.14, and 1.69±0.17 µg/g at 24 h post-injection, respectively.

In vivo toxicity evaluation
---------------------------

The in vivo toxicity of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex was evaluated with standard hematologic and biochemical analyses and by referring to the literature.[@b45-ijn-13-4607] Compared with the normal saline group, the HCT, HGB, RBC, WBC, MCV, MCH, and MCHC levels in the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex group showed no statistically significant differences, except for PLT ([Figure 11](#f11-ijn-13-4607){ref-type="fig"}). The ALT, AST, BUN, CREA, TP, ALB, and TBIL levels displayed no statistically significant difference between the normal saline group and the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex group ([Figure 12](#f12-ijn-13-4607){ref-type="fig"}).

In vivo MRI
-----------

For in vivo MR imaging, T~1~ and T~2~ dual-mode images were obtained pre- and post-injection of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex using a 3T MR scanner at room temperature. MRI images were collected at scheduled intervals of 24 h post-injection. As shown in [Figures 13](#f13-ijn-13-4607){ref-type="fig"} and [S7](#SD7-ijn-13-4607){ref-type="supplementary-material"}, compared with the pre-injection reference, a darker signal in T~2~-weighted images and a brighter signal in T~1~-weighted images in the kidney at 15 min after administration were observed. However, at the 6-h time point, such signal contrasts in the kidney brought by the nanocomplex injection became weaker and the signal contrasts in the bladder became stronger, indicating that the excretion of the nanocomplex was mainly via the kidneys and bladder. These results showed the potential of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex as an effective T~1~--T~2~ dual-mode CA for in vivo MRI with self-confirmation.

Discussion
==========

T~1~--T~2~ dual modal MR imaging avoids the false-positive signals caused by a single imaging mode and provides more accurate and complementary information. The development of T~1~--T~2~ dual CAs favors T~1~--T~2~ dual modal MR imaging. However, interferences between the T~1~ and T~2~ CAs when they are in proximity would reduce their MRI relaxivity. To avoid this influence, a 20-nm mSiO~2~ nanoshell was employed to increase the distance between T~1~ CA, BSA-Gd~2~O~3~ NP and the T~2~ CA, Fe~3~O~4~ NP in this study, because the interference of T~2~ CA on the contrast enhancement of paramagnetic T~1~ CAs might be weakened when their distance exceeds 12 nm. As expected, our fabricated Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex presented a comparable T~1~ relaxivity of 11.5 s^−1^ mM^−1^ to BSA-Gd~2~O~3~ (12.2 s^−1^ mM^−1^), which was three times that of the commercial MRI CAs, Gd--DTPA (*r*~1~ =4.3 s^−1^ mM^−1^). As reported, in a certain range, the larger the size of NPs, the stronger the saturation magnetization and relaxation rate of the nanomaterials.[@b46-ijn-13-4607] In our work, the existence of PDDA favored more BSA-Gd~2~O~3~ NPs loading on the surface of Fe~3~O~4~\@mSiO~2~ NPs. Therefore, the T~1~ relaxivity of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex should be higher than that of pure BSA-Gd~2~O~3~ NPs. However, there was little difference of T~1~ relaxivity between the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex and BSA-Gd~2~O~3~ NPs, which might arise from the interference of the Fe~3~O~4~ core, more or less. Besides the excellent MR imaging behaviors, the good biocompatibility and good stability in the cell culture medium or different pH solutions further provide the basis for their use to fabricate an mMRI nanoprobe. For hematologic analysis, all of the hematology markers displayed no statistically significant differences between the normal saline-treated group and the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex-treated group, except for PLTs. PLTs play a key role in hemostasis and thrombosis. Nanomaterials interact with PLTs and affect their count and function, which might result in severe clinical outcomes.[@b47-ijn-13-4607] For example, Radomski et al found multi- or single-walled carbon nanotubes (MWCNTs or SWCNTs) induced PLT activation and aggregation whereas C60 fullerences (nC60) had no effect.[@b48-ijn-13-4607] Reinish et al observed a reduction in the PLT blood count in the first 5 min after the injection of negatively charged liposomes to rats, but noted a recovery of PLT count after 60 min post-injection.[@b49-ijn-13-4607] Nanomaterial properties such as size, shape, chemical composition, and surface physicochemical property influence their effect on PLT, obviously. For biochemical analysis, the commonly used serum biochemical parameters including AST, ALT, TP, ALB, TBL, BUN, and CREA were measured. ALT and AST are commonly used indicators of liver function. Creatinine and BUN are important indicators of kidney function.[@b45-ijn-13-4607] Compared with the normal saline-treated group, no statistically significant difference was observed in the above parameters in the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex-treated group, showing the good biocompat-ibility of Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex in vivo. Then, after conjugation with the AS1411 aptamer as the targeting molecule, the 786-0 cells could be specifically targeted with the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3-~AS1411 nanoprobe by MRI. Furthermore, the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex could produce a signal enhancement in the kidney, suggesting their potential use as CAs in vivo. The biodistribution and clearance of nanomaterials in vivo is related to the characteristics of nanomaterials and organ specificity, such as hydrodynamic size, the surface charge, surface modification, and so on.[@b50-ijn-13-4607]--[@b52-ijn-13-4607] It was reported that NPs with a hydrodynamic diameter less than 5.5 nm could be excreted by renal clearance, and those with a hydrodynamic diameter more than 15 nm were usually captured and eliminated through the liver into bile and into feces.[@b53-ijn-13-4607],[@b54-ijn-13-4607] However, in our case, the increase of Gd concentration in the kidney with time indicated the possible excretion route of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex from the body through the kidneys, as even its hydrodynamic size was approximately 345.6 nm. This result was similar with that reported in Mekuria et al's report; they prepared G4.5-Gd~2~O~3~-PEG NPs with a hydrodynamic diameter of approximately 50 nm. They concluded that the kidneys removed NPs from the vascular compartment to the gall bladder.[@b55-ijn-13-4607] This means the clearance route of nanomaterials was not only related to the hydrodynamic size, but also to other factors. The Gd concentrations in the heart, liver, and lung all decreased with time, as indicated by the gradual clearance of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex from the body.

Conclusion
==========

The introduction of CAs has improved the sensitivity of MRI greatly, stimulating its wider application in disease diagnosis. However, single-mode CAs are not yet perfected. The combination of T~1~ and T~2~ CAs can integrate the high tissue resolution of T~1~ mode contrast imaging and the high feasibility of softer tissue detection of T~2~ mode contrast imaging. Herein, to get a T~1~--T~2~ dual MRI CA with better signal enhancement effect, a Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex was synthesized for better relaxivity of nano-CAs. The obtained nanocomplex displayed high longitudinal (*r*~1~=11.47 mM s^−1^ Gd) and transverse (*r*~2~=195.1 mM s^−1^ Fe) relaxivities, enabling its use as a T~1~--T~2~ dual CA for MRI. To further apply their use as mMR imaging nanoprobes for the specific recognition of tumor cells, the AS1411 aptamer which can specifically combine with the nucleolin of the surface of the tumor cell was covalently coupled with the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nano-complex. When intravenously injected into the mice, the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex could produce a kidney contrast-enhancement and was excreted via the bladder, thereby showing promise as a T~1~--T~2~ dual-mode CA.

Supplementary materials
=======================

###### 

Transmission electron microscopy characterizations of Fe~3~O~4~ nanoparticles (NPs) (**A**) and Fe~3~O~4~\@mSiO~2~ NPs (**B**). The insert in (**A**) is the distribution of Fe~3~O~4~ NP size.

###### 

X-ray powder diffraction patterns of the Fe~3~O~4~, Fe~3~O~4~\@mSiO~2~ and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex.

###### 

T~1~-weighted magnetic resonance (MR) images and T~1~-map images as well as T~2~-weighted MR images and T~2~-map images of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex prepared with different concentrations of Fe~3~O~4~ nanoparticles. A 3.0 T human MR scanner was used.

###### 

T~1~-weighted magnetic resonance (MR) images as well as T~2~-weighted MR images of the mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex, Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex, and Fe~3~O~4~\@mSiO~2~ nanocomplex. A 3.0 T human MR scanner was used.

###### 

T~1~-weighted magnetic resonance (MR) images and T~1~-map images as well as T~2~-weighted MR images and a T~2~-map images of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobe. No significant difference of T~1~ and T~2~ relaxation time could be observed after the AS1411 aptamer modification. A 3.0 T human MR scanner was used.

###### 

T~1~-weighted magnetic resonance (MR) images and T~1~-map images (**A**) as well as T~2~-weighted MR images and T~2~-map images (**B**) of NIH-3T3 cells treated with 1 mg mL^−1^ Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (−) and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobe (+). A 3.0 T human MR scanner was used.

###### 

(**A**) T~2~-weighted in vivo magnetic resonance imaging (MRI) images of mice post-injection of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex at different time points (0, 15 min, 6 h, and 24 h). The signal intensities in the kidneys (**B**) and bladder (**C**) at different time points after intravenous injection of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex. The red arrow indicates the kidney.

###### 

T~1~ and T~2~ relaxation time of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex prepared with different concentrations of Fe~3~O~4~ nanoparticles $(\overline{X} \pm S)$ (n=4)

  Group   Fe~3~O~4~ concentration (mg)   T~1~ relaxation time (ms)   T~2~ relaxation time (ms)
  ------- ------------------------------ --------------------------- ---------------------------
  1       1 mg                           318.25±3.86                 66.25±2.22
  2       3 mg                           448.75±7.93                 65.25±2.50
  3       5 mg                           453.25±6.29                 65.00±2.58

###### 

T~1~ and T~2~ relaxation time of the mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex, Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex and Fe~3~O~4~\@mSiO~2~ nanocomplex $(\overline{X} \pm S)$ (n=4)

  Group                               T~1~ relaxation time (ms)                                    T~2~ relaxation time (ms)
  ----------------------------------- ------------------------------------------------------------ ---------------------------------------------------------
  mSiO~2~/PDDA/Gd~2~O~3~              1,293.20±63.13[\*](#tfn1-ijn-13-4607){ref-type="table-fn"}   557.00±15.58[a](#tfn3-ijn-13-4607){ref-type="table-fn"}
  Fe~3~O~4~\@mSiO~2~/PDDA/Gd~2~O~3~   846.75±26.50[\#](#tfn2-ijn-13-4607){ref-type="table-fn"}     146.50±26.25
  Fe~3~O~4~\@mSiO~2~                  219.50±5.80                                                  149.25±12.63

**Notes:**

Refers to statistically significant differences when compared with the other two groups using one-way ANOVA (*p*\<0.05).

Refers to statistically significant differences when compared with the other two groups using one-way ANOVA (*p*\<0.05).

Refers to statistically significant differences when compared with the other two groups using one-way ANOVA (*p*\<0.05).

###### 

T~1~ relaxation time of NIH-3T3 mouse fibroblast cells and 786-0 renal carcinoma cells treated with 1 mg mL^−1^ Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (−) and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobe (+) $(\overline{X} \pm S)$ (n=4)

  Group       NIH-3T3 cells                                                786-0 cells
  ----------- ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------
  Control     1,823.80±18.84                                               1,752.80±2.50
  AS1411(+)   1,740.80±21.70[\*](#tfn4-ijn-13-4607){ref-type="table-fn"}   902.25±2.21[\#](#tfn5-ijn-13-4607){ref-type="table-fn"},[a](#tfn6-ijn-13-4607){ref-type="table-fn"}
  AS1411(−)   1,751.00±9.13[\*](#tfn4-ijn-13-4607){ref-type="table-fn"}    1,241.20±3.40[\#](#tfn5-ijn-13-4607){ref-type="table-fn"},[a](#tfn6-ijn-13-4607){ref-type="table-fn"}

**Notes:**

Refers to statistically significant differences when compared with control group using one-way ANOVA (*p*\<0.05).

Refers to statistically significant differences when compared with the control group using one-way ANOVA (*p*\<0.05).

Refers to statistically significant differences between NIH-3T3 and 786-0 cells with LSD Duncan (*p*\<0.05).

###### 

T~2~ relaxation time of NIH-3T3 mouse fibroblast cells and 786-0 renal carcinoma cells treated with 1 mg mL^−1^ Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (−) and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobe (+) $(\overline{X} \pm S)$ (n=4)

  Group       NIH-3T3 cells                                            786-0 cells
  ----------- -------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Control     132.50±9.95                                              129.00±2.94
  AS1411(+)   67.00±2.16[\*](#tfn7-ijn-13-4607){ref-type="table-fn"}   41.25±2.63[\#](#tfn8-ijn-13-4607){ref-type="table-fn"},[a](#tfn9-ijn-13-4607){ref-type="table-fn"}
  AS1411(−)   65.50±2.65[\*](#tfn7-ijn-13-4607){ref-type="table-fn"}   53.75±2.75[\#](#tfn8-ijn-13-4607){ref-type="table-fn"},[a](#tfn9-ijn-13-4607){ref-type="table-fn"}

**Notes:**

Refers to statistically significant differences when compared with the control group using one-way ANOVA (*p*\<0.05).

Refers to statistically significant differences when compared with the control group using one-way ANOVA (*p*\<0.05).

Refers to statistically significant differences NIH-3T3 and 786-0 cells with LSD Duncan (*p*\<0.05).
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![Characterization of the assembly process of Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ with zeta potential (**A**), hydrodynamic diameter determination (**B**), and the fabrication of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobe with fourier transform infrared absorption (FTIR) spectra (**C**) and UV-vis spectra (**D**).](ijn-13-4607Fig1){#f1-ijn-13-4607}

![T~1~-weighted magnetic resonance (MR) images and T~1~-map images as well as T~2~-weighted MR images and T~2~-map images of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex prepared with different concentrations of BSA-Gd~2~O~3~ NPs. 3.0 T human magnetic resonance scanner was used.](ijn-13-4607Fig2){#f2-ijn-13-4607}

![T~1~ and T~2~ relaxation time of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex prepared with different concentrations of BSA-Gd~2~O~3~ NPs. BSA-Gd~2~O~3~ NPs (0 µM) were treated as the control group, and other groups were all compared with the control group with one-way ANOVA. \*Refers to statistically significant differences compared with the control group with one-way ANOVA (*p*\<0.05). ^\#^Refers to statistically significant differences compared with control group with one-way ANOVA (*p*\<0.05). A 3.0 T human magnetic resonance scanner was used.](ijn-13-4607Fig3){#f3-ijn-13-4607}

![T~1~ relaxivity curves (**A**) and T~1~-weighted magnetic resonance (MR) images (**B**) of Gd-DTPA (1), BSA-Gd~2~O~3~ NPs (2), and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (3) with various Gd concentrations. A 3.0 T human MR scanner was used.](ijn-13-4607Fig4){#f4-ijn-13-4607}

![T~2~ relaxivity curves and T~2~-weighted magnetic resonance (MR) images of the Fe~3~O~4~ (**A**), and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (**B**) with various Fe~3~O~4~ nanoparticle concentrations. A 3.0 T human MR scanner was used.](ijn-13-4607Fig5){#f5-ijn-13-4607}

![Cell viability of 786-0 renal carcinoma cells and NIH-3T3 mouse fibroblast cells after exposure to various concentrations of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex, determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.](ijn-13-4607Fig6){#f6-ijn-13-4607}

![Iron and gadolinium ions released from the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex in cell culture medium over time (**A**) and in different pH solutions incubated for 24 h (**B**).](ijn-13-4607Fig7){#f7-ijn-13-4607}

![T~1~-weighted magnetic resonance (MR) images and T~1~-map images (**A**) as well as T~2~-weighted MR images and T~2~-map images (**B**) of 786-0 renal carcinoma cells treated with different concentrations of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (−) and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobe (+) (0, 0.5, 1, 2.5 mg/mL^−1^). A 3.0 T human MR scanner was used.](ijn-13-4607Fig8){#f8-ijn-13-4607}

![T~1~ (**A**) and T~2~ relaxation time (**B**) of 786-0 renal carcinoma cells treated with different concentrations of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (−) and Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobe (+).\
**Notes:** \*Refers to statistically significant differences compared with the control group using one-way ANOVA (*p*\<0.05). ^\#^Refers to statistically significant differences compared with the control group with one-way ANOVA (*p*\<0.05). ^a^Refers to statistically significant differences within group with LSD Duncan (*p*\<0.05). ^b^Refers to statistically significant differences within group with LSD Duncan (*p*\<0.05). ^c^Refers to statistically significant differences within group with LSD Duncan (*p*\<0.05). ^d^Refers to statistically significant differences within group with LSD Duncan (*p*\<0.05). A 3.0 T human magnetic resonance scanner was used.](ijn-13-4607Fig9){#f9-ijn-13-4607}

![The concentrations of Gd in the heart, lung, liver, and kidney at 1 h and 24 h post-intravenous injection of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex as determined by inductively coupled plasma-mass spectrometry (n=3, \**p*\<0.05, \*\**p*\<0.01).](ijn-13-4607Fig10){#f10-ijn-13-4607}

![Hematologic analysis of mice at 1 week post-injection of normal saline (black bar) and the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (red bar).\
**Notes:** (**A**) White blood cells (WBC), (**B**) red blood cells (RBC), (**C**) platelets (PLT), (**D**) mean corpuscular volume (MCV), (**E**) hemoglobin (HGB), (**F**) mean corpuscular hemoglobin concentration (MCHC), (**G**) mean corpuscular hemoglobin (MCH), and (**H**) hematocrit (HCT) levels in the blood. \*\*\*Refers to statistically significant differences compared with the normal saline group (*p*\<0.001, n=3).](ijn-13-4607Fig11){#f11-ijn-13-4607}

![Biochemical analysis of mice at 1 week post-injection of normal saline (black bar) and the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex (red bar).\
**Notes:** (**A**) Alanine transaminase (AST), (**B**) aspartate transaminase (ALT), (**C**) total protein (TP), (**D**) albumin (ALB), (**E**) total bilirubin (TBIL), (**F**) blood urea nitrogen (BUN), and (**G**) creatinine (CREA) levels in the blood; (n=3).](ijn-13-4607Fig12){#f12-ijn-13-4607}

![(**A**) T~1~-weighted in vivo magnetic resonance imaging (MRI) images of mice post-injection of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex at different time points (0, 15 min, 6 h, and 24 h). The signal intensities in the kidneys (**B**) and bladder (**C**) at different time points after intravenous injection of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~ nanocomplex. The red arrow indicates the kidney.](ijn-13-4607Fig13){#f13-ijn-13-4607}

![Schematic illustration of the fabrication process of the Fe~3~O~4~\@mSiO~2~/PDDA/BSA-Gd~2~O~3~-AS1411 nanoprobes.](ijn-13-4607Fig14){#f14-ijn-13-4607}

[^1]: These authors contributed equally to this work
